文献速递贫血与红细胞疾病

α地中海贫血与BCL11A基因与尼日利亚、美国、英国镰状细胞贫血队列卒中的关联

Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts.
PubMed 文献 · Blood Adv · 2017-01-01

在伊巴丹大学队列(n=249)中定义未继承α地中海贫血或BCL11A rs1427407 T等位基因的高危基因型,并在芝加哥伊利诺伊大学(n=260)与Walk-PHaSST(n=387)队列中重复验证;高危与溶血指标升高及卒中史相关,合并分析显示高危与卒中史相关(OR=2.0,95%CI:1.3至3.0,P=0.0002)。

要点

  • 高危基因型(未继承α地中海贫血或BCL11A rs1427407 T等位基因)与溶血指标升高及卒中史相关。
  • 合并分析中高危与卒中史相关(OR=2.0,95%CI:1.3至3.0,P=0.0002)。
  • 高危与频繁血管闭塞危象(≥3次/年)无关联。

核心结论

  • 高危基因型与三个独立队列中溶血增加及卒中史相关。
  • 该基因型可能有助于识别应优先使用羟基脲并加强卒中监测的患者。

研究设计与样本

  • 在伊巴丹大学队列(n=249)中研究高危基因型与临床及实验室变量的关联,并在芝加哥伊利诺伊大学(UIC)队列(n=260)和Walk-PHaSST队列(n=387)中重复验证。

主要发现

  • 伊巴丹队列中高危患者网织红细胞高于标准风险患者(15.0% vs. 7.8%,P=0.08),卒中史高于标准风险患者(6% vs. 1%,P=0.02)。
  • UIC队列中高危患者网织红细胞高于标准风险患者(13.5% vs. 11.8%,P=0.03),卒中史高于标准风险患者(32% vs. 22%,P=0.07)。
  • Walk-PHaSST队列中高危患者网织红细胞高于标准风险患者(9.6% vs. 8.2%,P=0.0003),卒中史高于标准风险患者(14% vs. 7%,P=0.01)。
  • 合并分析中高危与溶血指标升高相关:血红蛋白β=-0.29(95%CI:-0.50至-0.09;P=0.006),网织红细胞百分比β=2.29(95%CI:1.31至3.25;P=1x10-5)。
  • 合并分析中高危与卒中史相关(OR=2.0,95%CI:1.3至3.0;P=0.0002),但与频繁血管闭塞危象(≥3次/年)无关联。

临床怎么用

  • 作者认为该高危基因型可能有助于识别应优先使用羟基脲并加强卒中监测策略的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alpha-thalassemia and the BCL11A rs1427407 T allele are commonly observed in sickle cell anemia (SCA) patients and are associated with reduced hemolysis and higher hemoglobin F levels, respectively. We investigated whether a high-risk genetic profile, defined as SCA patients who did not inherit either α-thalassemia or the BCL11A rs1427407 T allele, had stronger associations with clinical and laboratory variables than the individual genetic components in the University of Ibadan cohort (n=249). We then replicated our findings in SCA cohorts from the University of Illinois at Chicago (UIC)(n=260) and Walk-Treatment of Pulmonary Hypertension and Sickle cell disease with Sildenafil Therapy (Walk-PHaSST)(n=387). High-risk was associated with higher reticulocytes (15.0% vs. 7.8%, P=0.08) and stroke history (6% vs. 1%, P=0.02) than standard risk patients and these associations were more significant than the individual genetic components in the University of Ibadan cohort. These findings were replicated in high-risk patients from UIC and Walk-PHaSST for reticulocytes (UIC: 13.5% vs. 11.8%, P=0.03; Walk-PHaSST: 9.6% vs. 8.2%, P=0.0003) and stroke history (UIC: 32% vs. 22%, P=0.07; Walk-PHaSST: 14% vs. 7%, P=0.01). On combined analysis, high-risk had strong associations with increased markers of hemolysis (hemoglobin β= -0.29, 95%CI: -0.50 to -0.09; P=0.006; reticulocyte% β=2.29, 95%CI: 1.31 to 3.25; P=1x10-5) and stroke history (OR=2.0, 95%CI: 1.3 to 3.0; P=0.0002), but no association with frequent vaso-occlusive crises (≥3/year). A high-risk genetic profile is associated with increased hemolysis and stroke history in three independent cohorts. This profile may help identify patients to prioritize for hydroxyurea and for closer monitoring strategies for stroke.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Saraf SL, Akingbola TS, Shah BN, et al. Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts. Blood Adv. 2017. PMID: 28868518. doi:10.1182/bloodadvances.2017005231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。